Advances and applications of Nanotechnology to solve Coronary Heart Disease

Yating Tang

doi:10.54097/hset.v36i.5724

Authors

Yating Tang

DOI:

https://doi.org/10.54097/hset.v36i.5724

Keywords:

Heart disease, Nanoparticle, Gene.

Abstract

Coronary heart disease is a common disease faced by human beings, regardless of age, there may be a risk of disease. But the sequelae of this disease are so high that bypass technology is not yet fully developed. Now for the solution of coronary heart disease is mainly in the study of nanoparticle implantation method, unlike modern bypass surgery years of medicine, can also recover well. This will greatly reduce the side effects of medicine on the body, and also save money. Nanotechnology will take a long time to make a clinical diagnosis and obtain a lot of evidence. The exact timing has not yet been determined, but it is clear that nanoparticles have potential.

Downloads

Download data is not yet available.

References

Karimi M, Zare H, Bakhshian Nik A, Yazdani N, Hamrang M, Mohamed E, Sahandi Zangabad P, Moosavi Basri SM, Bakhtiari L, Hamblin MR. Nanotechnology in diagnosis and treatment of coronary artery disease. Nanomedicine (Lond). Rhee JW, Wu JC. Advances in nanotechnology for the management of coronary artery disease [J]. Trends Cardiovasc Med. 2013 Feb;23(2):39-45.

Li Tao, & Qian Yongjun. (2019). Application of nanotechnology in coronary heart disease [J]. Journal of Clinical Cardiology (4), 4.

Hu XH, & Zhao ZP. (2013). Preparation and application of solid lipid nanoparticles for the treatment of coronary heart disease (CHD) [J]. CN103027981A.

Glen R. Boyd, Mary Ellen Tuccillo, Anne Sandvig, Miguel Pelaez, Changseok Han, & Dionysios D. Dionysiou [J]. (2013). Nanomaterials: Removal processes and beneficial applications in treatment. Journal (American Water Works Association), 105(12), E699–E708. http://www.jstor.org/stable/jamewatworass.105.12.e699

Chan, J. M., Rhee, J.-W., Drum, C. L., Bronson, R. T., Golomb, G., Langer, R., & Farokhzad, O. C. (2011). In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid—polymeric nanoparticles [J]. Proceedings of the National Academy of Sciences of the United States of America, 108(48), 19347–19352. http://www.jstor.org/stable/23066766

Ambesh P, Campia U, Obiagwu C, Bansal R, Shetty V, Hollander G, Shani J. Nanomedicine in coronary artery disease [J]. Indian Heart J. 2017 Mar-Apr;69(2):244-251.

Bejarano J, Navarro-Marquez M, Morales-Zavala F, Morales JO, Garcia-Carvajal I, Araya-Fuentes E, Flores Y, Verdejo HE, Castro PF, Lavandero S, Kogan MJ. Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches [J]. Theranostics. 2018 Sep 9.

Li T, Liang W, Xiao X, Qian Y. Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases [J]. Int J Nanomedicine. 2018 Nov 9; 13: 7349-7362.

https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronary-artery-disease-prevention-treatment-and-research

Elizabeth M. McNally, et al. Genetic mutations and mechanisms in dilated cardiomyopathy [J]. J Clin Invest. 2013;123(1):19-26.